158 related articles for article (PubMed ID: 15452764)
1. The burden of varicella in Germany. Potential risks and economic impact.
Banz K; Wagenpfeil S; Neiss A; Hammerschmidt T; Wutzler P
Eur J Health Econ; 2004 Feb; 5(1):46-53. PubMed ID: 15452764
[TBL] [Abstract][Full Text] [Related]
2. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany.
Wutzler P; Neiss A; Banz K; Goertz A; Bisanz H
Med Microbiol Immunol; 2002 Oct; 191(2):89-96. PubMed ID: 12410347
[TBL] [Abstract][Full Text] [Related]
3. Empirical data on the varicella situation in Germany for vaccination decisions.
Wagenpfeil S; Neiss A; Banz K; Wutzler P
Clin Microbiol Infect; 2004 May; 10(5):425-30. PubMed ID: 15113320
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of routine childhood varicella vaccination in Germany.
Banz K; Wagenpfeil S; Neiss A; Goertz A; Staginnus U; Vollmar J; Wutzler P
Vaccine; 2003 Mar; 21(11-12):1256-67. PubMed ID: 12559807
[TBL] [Abstract][Full Text] [Related]
5. [Impact of universal varicella vaccination in Germany: an epidemiological and economic analysis].
Knuf M; Neiss A; Wutzler P
Klin Padiatr; 2006; 218(4):203-12. PubMed ID: 16819701
[TBL] [Abstract][Full Text] [Related]
6. The economic value of childhood varicella vaccination in France and Germany.
Coudeville L; Brunot A; Szucs TD; Dervaux B
Value Health; 2005; 8(3):209-22. PubMed ID: 15877593
[TBL] [Abstract][Full Text] [Related]
7. Validation of health economic models: the example of EVITA.
Hammerschmidt T; Goertz A; Wagenpfeil S; Neiss A; Wutzler P; Banz K
Value Health; 2003; 6(5):551-9. PubMed ID: 14627061
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of varicella vaccination in Spain: results from a dynamic model.
Lenne X; Diez Domingo J; Gil A; Ridao M; Lluch JA; Dervaux B
Vaccine; 2006 Nov; 24(47-48):6980-9. PubMed ID: 16860909
[TBL] [Abstract][Full Text] [Related]
9. Varicella in Poland: economic burden in children 1-12 years of age in Poland, 2010-2015.
Wysocki J; Malecka I; Stryczynska-Kazubska J; Rampakakis E; Kuter B; Wolfson LJ
BMC Public Health; 2018 Mar; 18(1):410. PubMed ID: 29587714
[TBL] [Abstract][Full Text] [Related]
10. Economic burden of varicella in children 1-12 Years of age in Hungary, 2011-2015.
Meszner Z; Molnar Z; Rampakakis E; Yang HK; Kuter BJ; Wolfson LJ
BMC Infect Dis; 2017 Jul; 17(1):495. PubMed ID: 28705150
[TBL] [Abstract][Full Text] [Related]
11. Economic burden of varicella in children 1-12 years of age in Argentina, 2009-2014.
Giglio N; Monsanto H; Rampakakis E; Yang HK; Kuter BJ; Wolfson LJ
J Med Econ; 2018 Apr; 21(4):416-424. PubMed ID: 29357715
[TBL] [Abstract][Full Text] [Related]
12. Severe complications of varicella in previously healthy children in Germany: a 1-year survey.
Ziebold C; von Kries R; Lang R; Weigl J; Schmitt HJ
Pediatrics; 2001 Nov; 108(5):E79. PubMed ID: 11694663
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of varicella in Singapore--a cost benefit estimate of implementation of a routine varicella vaccination.
Jean-Jasmin LM; Lynette SP; Stefan M; Kai CS; Chew FT; Wah LB
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):693-6. PubMed ID: 15689089
[TBL] [Abstract][Full Text] [Related]
14. Healthcare costs associated with varicella and herpes zoster in Norway.
Haugnes H; Flem E; Wisløff T
Vaccine; 2019 Jun; 37(29):3779-3784. PubMed ID: 31151798
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of a routine varicella vaccination program for US children.
Lieu TA; Cochi SL; Black SB; Halloran ME; Shinefield HR; Holmes SJ; Wharton M; Washington AE
JAMA; 1994 Feb; 271(5):375-81. PubMed ID: 8283587
[TBL] [Abstract][Full Text] [Related]
16. Annual cost of hospitalization, inpatient rehabilitation and sick leave of anal cancer in Germany.
Heitland W; Schädlich PK; Chen X; Rémy V; Moro L
J Med Econ; 2013; 16(3):364-71. PubMed ID: 23253056
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases.
Bonanni P; Boccalini S; Bechini A; Banz K
Vaccine; 2008 Oct; 26(44):5619-26. PubMed ID: 18723062
[TBL] [Abstract][Full Text] [Related]
18. Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany.
Ehlken B; Ihorst G; Lippert B; Rohwedder A; Petersen G; Schumacher M; Forster J;
Eur J Pediatr; 2005 Oct; 164(10):607-15. PubMed ID: 15965766
[TBL] [Abstract][Full Text] [Related]
19. The burden and cost of hospitalised varicella and zoster in Australian children.
Carapetis JR; Russell DM; Curtis N
Vaccine; 2004 Dec; 23(6):755-61. PubMed ID: 15542199
[TBL] [Abstract][Full Text] [Related]
20. Cost of chickenpox in Canada: part II. Cost of complicated cases and total economic impact. The Immunization Monitoring Program-Active (IMPACT).
Law B; Fitzsimon C; Ford-Jones L; McCormick J; Rivière M
Pediatrics; 1999 Jul; 104(1 Pt 1):7-14. PubMed ID: 10390253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
